- Home
- INBX vs FULC Comparison
INBX vs FULC Comparison
Compare INBX & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INBX | FULC |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 430.2M | 468.1M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | INBX | FULC |
|---|---|---|
| Price | $76.74 | $12.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | 236.0K | ★ 2.6M |
| Earning Date | 11-14-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,400,000.00 | N/A |
| Revenue This Year | $563.00 | N/A |
| Revenue Next Year | $230.77 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2752.05 |
| 52 Week Low | $10.81 | $2.32 |
| 52 Week High | $94.47 | $15.74 |
Technical Indicators
Market Signals| Indicator | INBX | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 46.07 | 60.44 |
| Support Level | $79.00 | $12.56 |
| Resistance Level | $94.47 | $15.32 |
| Average True Range (ATR) | 5.90 | 1.27 |
| MACD | -2.08 | 0.25 |
| Stochastic Oscillator | 5.29 | 58.44 |
Price Performance
Historical ComparisonAbout INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.